Study Investigates Link Between Genetic Predisposition and Mesothelioma Cancer

LegalView Reports Results of a Breakthrough Study Investigating Link Between Genetic Predisposition and Developing Mesothelioma Cancer

LegalView informed readers to the results of a scientific investigation studying the potential link between genetic components and developing mesothelioma cancer. Scientists determined that genetic responses occurred after a specific type of asbestos was introduced to cells within the lining of the lungs.

Denver, CO, September 01 -- LegalView.com, the number one legal resource available on the Web, offered updated details on its mesothelioma information blog of an advanced scientific investigation studying the link between asbestos and genetics. Researchers, who found a genetic response to a specific type of asbestos known as crocidolite, published their findings in an August 2008 issue of BMC Genetics. The study, a first of its kind, used a methodology of exposing cells within the human lung lining to asbestos and then scientists watched the reaction and changes. The study offers mesothelioma victims a unprecedented look into how asbestos affects the human body. Victims were also provided with a gleam of progress on finding a cure for the condition, although the scientists stated more research is required.

Individuals who are suffering from an asbestos-related disease are advised to contact a mesothelioma law firm that can provide access to a wealth of knowledgeable mesothelioma attorneys. Because mesothelioma cancer is incurable and is commonly considered a preventable illness, discussing the details of a potential mesothelioma lawsuit with a mesothelioma lawyer may provide insight as to how monetary compensation could be awarded to aid in the costly medical bills associated with mesothelioma.

In their study, the researchers reported that asbestosis occurs in nearly 200,000 individuals each year with an additional 4,000 asbestos-related deaths occurring annually as well. Asbestos is a type of mineral that was mined for use in insulation because of its fire-retardant qualities and inexpensive production costs. However, inhaling asbestos fibers has led to a severe and incurable form of lung cancer known as mesothelioma. Millions of Americans may have been exposed to asbestos fibers during the 20th century, as asbestos was heavily mined and often used during the construction of buildings such as elementary schools, universities, hospitals, office buildings, homes and apartments.

In addition to mesothelioma information, LegalView houses a library of other legal issues potentially causing harm to everyday Americans. Also, due to the ongoing crisis among the pharmaceutical community, LegalView has provided updated information on several pharmaceutical drug's side effects and dangers. Among the drugs are Ketek as well as Levaquin and Cipro, both of the fluoroquinolone family.

Ketek (telithromycin) is an antibiotic used to treat conditions such as community-acquired pneumonia, bronchitis, sinusitis and other upper respiratory infections. The antibiotic is manufactured by Sanofi-Aventis and has been available to the market since 2004, however, since its release, the U.S. Food and Drug Administration (FDA) has reported nearly 20 deaths of individuals consuming the medication. The deaths all involved the development of liver damage among the patients who died as well as an additional 100 patients who also reported signs and symptoms of liver disease while taking Ketek. Those who have consumed Ketek and feel they exhibit any of the side effects commonly associated with liver disease, such as jaundice or yellowing of the skin, should seek medical assistance immediately. Additionally, it may be advisable for an individual to be involved with a Ketek class action lawsuit and contacting an experienced pharmaceutical lawyer will assist with any legal action necessary.

Levaquin (levofloxacin) and Cipro (ciprofloaxacin), similar to Ketek, are also antibiotics that treat bacterial infections such as bronchitis, although, in July 2008 the FDA gave all of the fluoroquinolone drugs an increased warning label known as the "black box" warning label, the harshest warning given by the FDA. The warning label was increased because the Levaquin and Cipro risks had been previously linked to tendon rupture among patients, according to several studies including one published in Clinical Rheumatology in February 2004. The black box warning is to encourage physicians to avoid prescribing these drugs to patients who may be at a greater risk for Achilles tendon rupture, including elderly patients.

LegalView provides a vast array of resources for individuals plagued by legal misfortune so that they may positively improve their situation and have the tools necessary to do so, including the recently updated Zimmer Durom cup information portal. The Zimmer Durom cup is an artificial hip component used during hip replacement surgery among patients. However, Zimmer Holdings, manufacturers of the product, recently halted the production of the hip socket after hundreds of doctors complained that the medical device was failing among patients. To learn more about the potential for a Zimmer Durom cup recall, visit the LegalView homepage at http://www.LegalView.com/.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.

Contact Information
LegalView
Katie Kelley
720-771-3246
press-releases@legalview.com
www.legalview.com

---

Mesothelioma Treatment Video
Bengoshi-san
Accident Injury Compensation

Visual Reference for Neurosurgeons Published

A Concise and Visual Reference for Neurosurgeons Published in Conjunction with the American Association of Neurological Surgeons

New York, NY, November 26, 2008 -- Every year approximately 30,000 patients in the United States suffer from a ruptured cerebral aneurysm. And according to the American Association of Neurological Surgeons (AANS), up to six percent of the population may have an unruptured one. Managing such a serious medical condition poses significant challenges for patients as well as their treating physicians. Vascular Neurosurgery, co-published by Thieme and the AANS, includes one section devoted to aneurysms and subarchnoid hemorrhage. The book is a step-by-step guide to management, preoperative evaluation, surgical technique, and postoperative management. It is currently the only text in the field that provides concise visual chapters on how to carry out such surgical procedures.

The second edition of Vascular Neurosurgery is a new volume in the classic Neurosurgical Operative Atlas series. This detailed atlas, which offers surgical approaches to common neurovascular diseases and conditions, was developed to "meet the needs of residents and neurosurgeons particularly when it comes to learning how to conduct an operation, brushing up on a technique, or just finding out how others do things," says editor Dr. R. Loch Macdonald, head of the division of neurosurgery at the University of Toronto, in Toronto Ontario.

The book contains more than 300 illustrations that vividly demonstrate surgical steps and techniques. One of the many appealing aspects of the atlas lies in its brevity. Each chapter can be read within thirty minutes, enabling a physician or resident to quickly page through the book prior to surgery.

This practical surgical reference is not only useful for prepping for oral board examinations; it is also an asset to clinicians in neurosurgery and vascular surgery. Vascular Neurosurgery is one in an ongoing series of books co-published by Thieme and the American Association of Neurological Surgeons. The five volume set, edited by leading experts in the field, covers the entire spectrum of neurosurgery. Other titles in the series include, Neuro-Oncology, Spine and Peripheral Nerves, Pediatric Neurosurgery, and Functional Neurosurgery.

About the American Association of Neurological Surgeons

The American Association of Neurological Surgeons (AANS) is the organization that speaks for all of neurosurgery. The AANS is dedicated to advancing the specialty of neurological surgery in order to promote the highest quality of patient care.

About Thieme

Thieme Publishing Group is a privately held scientific and medical publishing house employing more than 950 people and maintaining offices in seven cities, including New York, Delhi, Stuttgart and three other locations in Germany. Founded in 1886, the Thieme name has become synonymous with high quality and excellence in medical and scientific publishing. Today, Thieme is the market leading publisher of neurosurgical content and holds strong market positions in orthopedics, radiology, anatomy and chemistry, among other specialties. Thieme publishes 137 peer-reviewed journals and over 500 new books annually. The company also has a rapidly growing array of web-based products in medicine and science. Popular online products include Thieme eJournals and the Thieme Electronic Book Library, which are accessible via thieme-connect.com, Thieme's platform for electronic products. New anatomy resources include the thiemeteachingassistant.com for faculty, and winkingskull.com for students. Please visit thieme.com for additional information.

Contact Information
Thieme Publishers
Bettina Ziegler
+49-711-8931-488
bettina.ziegler@thieme.de
www.thieme.com

---

Manufacturing Simulation Software
Steam Shower Saunas
Heat Pump Technology
Mesothelioma Prognosis

Market Growing For Surgical Sealants, Glues, Wound Closure, and Anti-Adhesion Products

Surgical Sealants, Glues, Wound Closure, Anti-Adhesion, Worldwide; MedMarket Diligence Report

MedMarket Diligence tracks wound closure, hemostasis and anti-adhesion technologies and forecasts this market in a forthcoming worldwide report, with insight into market introduction, growth, competition and business opportunity.

Foothill Ranch, CA, November 18, 2008 -- Opportunities for products in wound closure, hemostasis and anti-adhesion products are plentiful for established and emerging companies, driven by innovation in product formulation and penetration of more caseload, including growth in more medical and surgical specialties. The market for these products is also growing through their expansion globally, with products being introduced and finding clinical acceptance in the U.S., Europe, Central and South America and other markets globally.

MedMarket Diligence monitors and identifies emergence and growth of novel technologies in wound closure, hemostasis and anti-adhesion and applies its industry awareness and analysis to providing insight into market introduction, growth, competition and opportunity worldwide. The products, current and forecast markets, companies and opportunities are detailed in this 2008 report from MedMarket Diligence. The report details the markets worldwide, with detailed geographic segmentation, for surgical sealants, glues, hemostats, sutures, tapes, and other wound closure technologies, as well as products for the prevention of post-surgical adhesion.

"The use of these biologicals and other product forms, once representing a minor share of wound closure, has now moved into the mainstream, with sealant, closure, hemostasis and combinations of uses by these products eclipsing use by traditional wound closure devices," says Patrick Driscoll, president of MedMarket Diligence. According to Driscoll, the market is also experiencing increased competition and market evolution as new products are introduced and some consolidation is taking place even while the number and types of procedures target by these products proliferate. A number of market leaders have solidified their positions within the surgical closure and securement markets through successful internal development programs and through technology partnerships with innovative vendors of next generation technologies.

MedMarket Diligence's comprehensive analysis of the market for surgical sealants, glues/adhesives, hemostats, tapes, sutures, and anti-adhesion products is a worldwide report that is a must have tool for market planning, strategic analysis and positioning in this large and growing market. The report details the products on the market, their current and forecast penetration of clinical application, new products under development and their status, the current and forecast market for products by major country markets worldwide, and the current and hopeful competitors in the market and their positions, strengths and strategies. The report provides specific forecasts and shares of the worldwide market by segment for the U.S., Europe (United Kingdom, Germany, France, Italy, BeNeLux), Latin America, Japan and Rest of World.

The report is scheduled for publication in early December 2008. The report is described with table of contents (list of exhibits pending) at http://mediligence.com/rpt/rpt-s175.hm. A pre-paid discount is available and the report may be purchased at https://www.mediligence.com/store/page29.html or via order form (http://www.mediligence.com/order_forms/s175_order.pdf).

Contact Information

MedMarket Diligence, LLC
Patrick Driscoll
949-859-3401
patrick@mediligence.com
www.mediligence.com

---

Compulsive Gamer
Validation Company
Accident Lawyer Minneapolis
Lower Back Pain